line core busi appear
net dbt
line maintain estim roll
report adj ep estimate line item line
consensu core dialysi busi continu outperform off-set wors
expect ancillary/intern result maintain op inc guidanc
provid januari overal quarter larg line although slow
organ growth wors expect price like focu maintain
oper incom estim adjust ep estim tax
time share repo also roll est reaffirm buy core dialysi
result remain solid see upsid potenti signific capit catalyst
revenu lower expect better
store treatment growth deceler vs total
treatment still came estim meanwhil lower expect dialysi
price ancillary/intern revenu drove total revenu
estimate/consensu patient care cost line estim
better overal adjust oper incom line estim
line item drove ep lower estim
expect maintain oper incom guidanc provid
januari meanwhil compani provid oper cash flow guidanc lower
estim tax rate guidanc slightli higher expect overal feel
good guidanc core dialysi busi appear track upsid
question call
updat commerci mix price organ treatment growth outlook time
davita medic group dmg sale share repo color dialysi ballot
legisl environ includ ab california
full definit iqmethod sm measur see page
bofa merril lynch seek busi issuer cover research report
result investor awar firm may conflict interest could
affect object report investor consid report singl
factor make invest decis
refer import disclosur page analyst certif page price object
basis/risk page
return capit employ
return equiti
iqmethod sm qualiti earn
net incom cont oper
chang work capit
full definit iqmethod sm measur see page
davita inc lead dialysi provid
unit state compani oper
outpati clinic us serv
patient also oper countri
outsid us
sale davita medic group dmg
posit use bulk proce
share repurchas still pay debt
make increment invest
health care servic outsid dialysi
po base ebitda estim around high end
stand-alon histor rang ebitda dmg sale allow
focu core dialysi busi deploy capit
upsid risk po commerci mix better expect
reimburs better expect make chang third
downsid risk po commerci price pressur could continu
potenti commerci mix pressur manag care vast major dialysi
kevin fischbeck cfa herebi certifi view express research report
accur reflect person view subject secur issuer also
certifi part compens directli indirectli relat
specif recommend view express research report
us facil hospit manag healthcar coverag cluster
qualiti earn
iqmethod smi set bofa merril lynch standard measur serv maintain global consist three broad head busi perform qualiti earn valid key featur
iqmethod consist structur detail transpar methodolog guidelin maxim effect compar valuat process identifi common pitfal
iqdatabas real-tim global research databas sourc directli equiti analyst earn model includ forecast well histor data incom statement balanc sheet cash
flow statement compani cover bofa merril lynch
iqprofil sm iqmethod sm servic mark america corpor iqdatabas regist servic mark america corpor
